aluates Reports

$ 0.0

Automative

Global Live Herpes Zoster Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: November 2025

Report Code: QYRE-Auto-36P17034

Global Live Herpes Zoster Vaccine Market Research Report 2024

BUY CHAPTERS

Global Live Herpes Zoster Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-36P17034

Report

November 2025

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Merck

GSK

Changchun BCHT Biotechnology

SIBP CNBG

Live Herpes Zoster Vaccine Market

The global Live Herpes Zoster Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Live Herpes Zoster Vaccine refers to a vaccine used to prevent shingles. Shingles is a disease caused by the varicella-zoster virus, which usually reoccurs years after a chickenpox infection. This vaccine is attenuated, using a live virus strain that has been weakened, hence the name attenuated vaccine. Vaccination with the attenuated shingles vaccine can help prevent or reduce episodes of shingles and reduce the risk of complications. (Now all companies have achieved commercial production, except for SIBP CNBG, which is in the Phase II experimental stage.)

From a downstream perspective, Public Health Sector accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Live Herpes Zoster Vaccine leading manufacturers including Merck, GSK, SK, Changchun BCHT Biotechnology, SIBP CNBG, etc., dominate supply; the top five capture approximately % of global revenue, with Merck leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Live Herpes Zoster Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Live Herpes Zoster Vaccine Market Report

Report Metric	Details
Report Name	Live Herpes Zoster Vaccine Market
Segment by Type	Single-dose Vaccination Double-dose Vaccination
Segment by Application	Public Health Sector Hospitals & clinics Others
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck, GSK, SK, Changchun BCHT Biotechnology, SIBP CNBG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Live Herpes Zoster Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Live Herpes Zoster Vaccine Market report?

Ans: The main players in the Live Herpes Zoster Vaccine Market are Merck, GSK, SK, Changchun BCHT Biotechnology, SIBP CNBG

What are the Application segmentation covered in the Live Herpes Zoster Vaccine Market report?

Ans: The Applications covered in the Live Herpes Zoster Vaccine Market report are Public Health Sector, Hospitals & clinics, Others

What are the Type segmentation covered in the Live Herpes Zoster Vaccine Market report?

Ans: The Types covered in the Live Herpes Zoster Vaccine Market report are Single-dose Vaccination, Double-dose Vaccination

1 Study Coverage

1.1 Introduction to Live Herpes Zoster Vaccine: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Live Herpes Zoster Vaccine Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Single-dose Vaccination

1.2.3 Double-dose Vaccination

1.3 Market Segmentation by Application

1.3.1 Global Live Herpes Zoster Vaccine Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Public Health Sector

1.3.3 Hospitals & clinics

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Live Herpes Zoster Vaccine Revenue Estimates and Forecasts 2020-2031

2.2 Global Live Herpes Zoster Vaccine Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Live Herpes Zoster Vaccine Sales Estimates and Forecasts 2020-2031

2.4 Global Live Herpes Zoster Vaccine Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Live Herpes Zoster Vaccine Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Live Herpes Zoster Vaccine Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Single-dose Vaccination Market Size by Manufacturers

3.5.2 Double-dose Vaccination Market Size by Manufacturers

3.6 Global Live Herpes Zoster Vaccine Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Live Herpes Zoster Vaccine Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Live Herpes Zoster Vaccine Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Live Herpes Zoster Vaccine Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Live Herpes Zoster Vaccine Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Live Herpes Zoster Vaccine Sales and Revenue by Type (2020-2031)

6.4 North America Live Herpes Zoster Vaccine Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Live Herpes Zoster Vaccine Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Live Herpes Zoster Vaccine Sales and Revenue by Type (2020-2031)

7.4 Europe Live Herpes Zoster Vaccine Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Live Herpes Zoster Vaccine Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Live Herpes Zoster Vaccine Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Live Herpes Zoster Vaccine Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Live Herpes Zoster Vaccine Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Live Herpes Zoster Vaccine Sales and Revenue by Type (2020-2031)

9.4 Central and South America Live Herpes Zoster Vaccine Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Live Herpes Zoster Vaccine Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Live Herpes Zoster Vaccine Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Live Herpes Zoster Vaccine Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Live Herpes Zoster Vaccine Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Merck

11.1.1 Merck Corporation Information

11.1.2 Merck Business Overview

11.1.3 Merck Live Herpes Zoster Vaccine Product Models, Descriptions and Specifications

11.1.4 Merck Live Herpes Zoster Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Merck Live Herpes Zoster Vaccine Sales by Product in 2024

11.1.6 Merck Live Herpes Zoster Vaccine Sales by Application in 2024

11.1.7 Merck Live Herpes Zoster Vaccine Sales by Geographic Area in 2024

11.1.8 Merck Live Herpes Zoster Vaccine SWOT Analysis

11.1.9 Merck Recent Developments

11.2 GSK

11.2.1 GSK Corporation Information

11.2.2 GSK Business Overview

11.2.3 GSK Live Herpes Zoster Vaccine Product Models, Descriptions and Specifications

11.2.4 GSK Live Herpes Zoster Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 GSK Live Herpes Zoster Vaccine Sales by Product in 2024

11.2.6 GSK Live Herpes Zoster Vaccine Sales by Application in 2024

11.2.7 GSK Live Herpes Zoster Vaccine Sales by Geographic Area in 2024

11.2.8 GSK Live Herpes Zoster Vaccine SWOT Analysis

11.2.9 GSK Recent Developments

11.3 SK

11.3.1 SK Corporation Information

11.3.2 SK Business Overview

11.3.3 SK Live Herpes Zoster Vaccine Product Models, Descriptions and Specifications

11.3.4 SK Live Herpes Zoster Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 SK Live Herpes Zoster Vaccine Sales by Product in 2024

11.3.6 SK Live Herpes Zoster Vaccine Sales by Application in 2024

11.3.7 SK Live Herpes Zoster Vaccine Sales by Geographic Area in 2024

11.3.8 SK Live Herpes Zoster Vaccine SWOT Analysis

11.3.9 SK Recent Developments

11.4 Changchun BCHT Biotechnology

11.4.1 Changchun BCHT Biotechnology Corporation Information

11.4.2 Changchun BCHT Biotechnology Business Overview

11.4.3 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine Product Models, Descriptions and Specifications

11.4.4 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine Sales by Product in 2024

11.4.6 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine Sales by Application in 2024

11.4.7 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine Sales by Geographic Area in 2024

11.4.8 Changchun BCHT Biotechnology Live Herpes Zoster Vaccine SWOT Analysis

11.4.9 Changchun BCHT Biotechnology Recent Developments

11.5 SIBP CNBG

11.5.1 SIBP CNBG Corporation Information

11.5.2 SIBP CNBG Business Overview

11.5.3 SIBP CNBG Live Herpes Zoster Vaccine Product Models, Descriptions and Specifications

11.5.4 SIBP CNBG Live Herpes Zoster Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 SIBP CNBG Live Herpes Zoster Vaccine Sales by Product in 2024

11.5.6 SIBP CNBG Live Herpes Zoster Vaccine Sales by Application in 2024

11.5.7 SIBP CNBG Live Herpes Zoster Vaccine Sales by Geographic Area in 2024

11.5.8 SIBP CNBG Live Herpes Zoster Vaccine SWOT Analysis

11.5.9 SIBP CNBG Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Live Herpes Zoster Vaccine Industry Chain

12.2 Live Herpes Zoster Vaccine Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Live Herpes Zoster Vaccine Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Live Herpes Zoster Vaccine Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Live Herpes Zoster Vaccine Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Live Herpes Zoster Vaccine Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Merck

GSK

Changchun BCHT Biotechnology

SIBP CNBG

List of Tables

Table 1. Global Live Herpes Zoster Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Live Herpes Zoster Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Live Herpes Zoster Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Live Herpes Zoster Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Live Herpes Zoster Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)

Table 7. Global Live Herpes Zoster Vaccine Sales by Region (2020-2025) & (K Dose)

Table 8. Global Live Herpes Zoster Vaccine Sales by Region (2026-2031) & (K Dose)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Live Herpes Zoster Vaccine Sales by Manufacturers (2020-2025) & (K Dose)

Table 11. Global Live Herpes Zoster Vaccine Sales Share by Manufacturers (2020-2025)

Table 12. Global Live Herpes Zoster Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Live Herpes Zoster Vaccine Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Live Herpes Zoster Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Herpes Zoster Vaccine as of 2024)

Table 16. Global Live Herpes Zoster Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Live Herpes Zoster Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)

Table 18. Key Manufacturers Live Herpes Zoster Vaccine Manufacturing Base and Headquarters

Table 19. Global Live Herpes Zoster Vaccine Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Live Herpes Zoster Vaccine Sales by Type (2020-2025) & (K Dose)

Table 23. Global Live Herpes Zoster Vaccine Sales by Type (2026-2031) & (K Dose)

Table 24. Global Live Herpes Zoster Vaccine Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Live Herpes Zoster Vaccine Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Live Herpes Zoster Vaccine ASP by Type (2020-2031) & (US$/Dose)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Live Herpes Zoster Vaccine Sales by Application (2020-2025) & (K Dose)

Table 29. Global Live Herpes Zoster Vaccine Sales by Application (2026-2031) & (K Dose)

Table 30. Live Herpes Zoster Vaccine High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Live Herpes Zoster Vaccine Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Live Herpes Zoster Vaccine Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Live Herpes Zoster Vaccine ASP by Application (2020-2031) & (US$/Dose)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Live Herpes Zoster Vaccine Growth Accelerators and Market Barriers

Table 37. North America Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Live Herpes Zoster Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Live Herpes Zoster Vaccine Growth Accelerators and Market Barriers

Table 40. Europe Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Live Herpes Zoster Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Live Herpes Zoster Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Live Herpes Zoster Vaccine Growth Accelerators and Market Barriers

Table 45. Southeast Asia Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Live Herpes Zoster Vaccine Investment Opportunities and Key Challenges

Table 47. Central and South America Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Live Herpes Zoster Vaccine Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Live Herpes Zoster Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Merck Corporation Information

Table 51. Merck Description and Major Businesses

Table 52. Merck Product Models, Descriptions and Specifications

Table 53. Merck Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 54. Merck Sales Value Proportion by Product in 2024

Table 55. Merck Sales Value Proportion by Application in 2024

Table 56. Merck Sales Value Proportion by Geographic Area in 2024

Table 57. Merck Live Herpes Zoster Vaccine SWOT Analysis

Table 58. Merck Recent Developments

Table 59. GSK Corporation Information

Table 60. GSK Description and Major Businesses

Table 61. GSK Product Models, Descriptions and Specifications

Table 62. GSK Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 63. GSK Sales Value Proportion by Product in 2024

Table 64. GSK Sales Value Proportion by Application in 2024

Table 65. GSK Sales Value Proportion by Geographic Area in 2024

Table 66. GSK Live Herpes Zoster Vaccine SWOT Analysis

Table 67. GSK Recent Developments

Table 68. SK Corporation Information

Table 69. SK Description and Major Businesses

Table 70. SK Product Models, Descriptions and Specifications

Table 71. SK Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 72. SK Sales Value Proportion by Product in 2024

Table 73. SK Sales Value Proportion by Application in 2024

Table 74. SK Sales Value Proportion by Geographic Area in 2024

Table 75. SK Live Herpes Zoster Vaccine SWOT Analysis

Table 76. SK Recent Developments

Table 77. Changchun BCHT Biotechnology Corporation Information

Table 78. Changchun BCHT Biotechnology Description and Major Businesses

Table 79. Changchun BCHT Biotechnology Product Models, Descriptions and Specifications

Table 80. Changchun BCHT Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 81. Changchun BCHT Biotechnology Sales Value Proportion by Product in 2024

Table 82. Changchun BCHT Biotechnology Sales Value Proportion by Application in 2024

Table 83. Changchun BCHT Biotechnology Sales Value Proportion by Geographic Area in 2024

Table 84. Changchun BCHT Biotechnology Live Herpes Zoster Vaccine SWOT Analysis

Table 85. Changchun BCHT Biotechnology Recent Developments

Table 86. SIBP CNBG Corporation Information

Table 87. SIBP CNBG Description and Major Businesses

Table 88. SIBP CNBG Product Models, Descriptions and Specifications

Table 89. SIBP CNBG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 90. SIBP CNBG Sales Value Proportion by Product in 2024

Table 91. SIBP CNBG Sales Value Proportion by Application in 2024

Table 92. SIBP CNBG Sales Value Proportion by Geographic Area in 2024

Table 93. SIBP CNBG Live Herpes Zoster Vaccine SWOT Analysis

Table 94. SIBP CNBG Recent Developments

Table 95. Key Raw Materials Distribution

Table 96. Raw Materials Key Suppliers

Table 97. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 98. Milestones in Production Technology Evolution

Table 99. Distributors List

Table 100. Market Trends and Market Evolution

Table 101. Market Drivers and Opportunities

Table 102. Market Challenges, Risks, and Restraints

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

List of Figures

Figure 1. Live Herpes Zoster Vaccine Product Picture

Figure 2. Global Live Herpes Zoster Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Single-dose Vaccination Product Picture

Figure 4. Double-dose Vaccination Product Picture

Figure 5. Global Live Herpes Zoster Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Public Health Sector

Figure 7. Hospitals & clinics

Figure 8. Others

Figure 9. Live Herpes Zoster Vaccine Report Years Considered

Figure 10. Global Live Herpes Zoster Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 12. Global Live Herpes Zoster Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Live Herpes Zoster Vaccine Revenue Market Share by Region (2020-2031)

Figure 14. Global Live Herpes Zoster Vaccine Sales (2020-2031) & (K Dose)

Figure 15. Global Live Herpes Zoster Vaccine Sales (CAGR) by Region (2020-2031) (K Dose)

Figure 16. Global Live Herpes Zoster Vaccine Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers Live Herpes Zoster Vaccine Sales Volume Market Share in 2024

Figure 18. Global Live Herpes Zoster Vaccine Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Single-dose Vaccination Revenue Market Share by Manufacturer in 2024

Figure 21. Double-dose Vaccination Revenue Market Share by Manufacturer in 2024

Figure 22. Global Live Herpes Zoster Vaccine Sales Market Share by Type (2020-2031)

Figure 23. Global Live Herpes Zoster Vaccine Revenue Market Share by Type (2020-2031)

Figure 24. Global Live Herpes Zoster Vaccine Sales Market Share by Application (2020-2031)

Figure 25. Global Live Herpes Zoster Vaccine Revenue Market Share by Application (2020-2031)

Figure 26. North America Live Herpes Zoster Vaccine Sales YoY (2020-2031) & (K Dose)

Figure 27. North America Live Herpes Zoster Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 28. North America Top 5 Manufacturers Live Herpes Zoster Vaccine Sales Revenue (US$ Million) in 2024

Figure 29. North America Live Herpes Zoster Vaccine Sales Volume (K Dose) by Type (2020- 2031)

Figure 30. North America Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 31. North America Live Herpes Zoster Vaccine Sales Volume (K Dose) by Application (2020-2031)

Figure 32. North America Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 33. US Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 34. Canada Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 35. Mexico Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 36. Europe Live Herpes Zoster Vaccine Sales YoY (2020-2031) & (K Dose)

Figure 37. Europe Live Herpes Zoster Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 38. Europe Top 5 Manufacturers Live Herpes Zoster Vaccine Sales Revenue (US$ Million) in 2024

Figure 39. Europe Live Herpes Zoster Vaccine Sales Volume (K Dose) by Type (2020-2031)

Figure 40. Europe Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 41. Europe Live Herpes Zoster Vaccine Sales Volume (K Dose) by Application (2020-2031)

Figure 42. Europe Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. Germany Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 44. France Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 45. U.K. Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 46. Italy Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 47. Russia Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 48. Asia-Pacific Live Herpes Zoster Vaccine Sales YoY (2020-2031) & (K Dose)

Figure 49. Asia-Pacific Live Herpes Zoster Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Top 8 Manufacturers Live Herpes Zoster Vaccine Sales Revenue (US$ Million) in 2024

Figure 51. Asia-Pacific Live Herpes Zoster Vaccine Sales Volume (K Dose) by Type (2020- 2031)

Figure 52. Asia-Pacific Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 53. Asia-Pacific Live Herpes Zoster Vaccine Sales Volume (K Dose) by Application (2020-2031)

Figure 54. Asia-Pacific Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Indonesia Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 56. Japan Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 57. South Korea Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 58. China Taiwan Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 59. India Live Herpes Zoster Vaccine Revenue (2020-2031) & (US$ Million)

Figure 60. Central and South America Live Herpes Zoster Vaccine Sales YoY (2020-2031) & (K Dose)

Figure 61. Central and South America Live Herpes Zoster Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Central and South America Top 5 Manufacturers Live Herpes Zoster Vaccine Sales Revenue (US$ Million) in 2024

Figure 63. Central and South America Live Herpes Zoster Vaccine Sales Volume (K Dose) by Type (2021-2031)

Figure 64. Central and South America Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 65. Central and South America Live Herpes Zoster Vaccine Sales Volume (K Dose) by Application (2020-2031)

Figure 66. Central and South America Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Brazil Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 68. Argentina Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 69. Middle East, and Africa Live Herpes Zoster Vaccine Sales YoY (2020-2031) & (K Dose)

Figure 70. Middle East and Africa Live Herpes Zoster Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 71. Middle East and Africa Top 5 Manufacturers Live Herpes Zoster Vaccine Sales Revenue (US$ Million) in 2024

Figure 72. Middle East and Africa Live Herpes Zoster Vaccine Sales Volume (K Dose) by Type (2021-2031)

Figure 73. South America Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 74. Middle East and Africa Live Herpes Zoster Vaccine Sales Volume (K Dose) by Application (2020-2031)

Figure 75. Middle East and Africa Live Herpes Zoster Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 76. GCC Countries Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 77. Turkey Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 78. Egypt Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 79. South Africa Live Herpes Zoster Vaccine Revenue (2020-2025) & (US$ Million)

Figure 80. Live Herpes Zoster Vaccine Industry Chain Mapping

Figure 81. Regional Live Herpes Zoster Vaccine Manufacturing Base Distribution (%)

Figure 82. Global Live Herpes Zoster Vaccine Production Market Share by Region (2020-2031)

Figure 83. Live Herpes Zoster Vaccine Production Process

Figure 84. Regional Live Herpes Zoster Vaccine Production Cost Structure

Figure 85. Channels of Distribution (Direct Vs Distribution)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Varicella Live Vaccine Market Insights Forecast to 2030

Zoster Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Varicella Virus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Live Attenuated Herpes Zoster Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Varicella Attenuated Live Vaccine Market Research Report 2025

Global Varicella Attenuated Live Vaccination Market Research Report 2025

Global Poultry Live Attenuated Vaccine Market Research Report 2024

Chickenpox Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Zoster Vaccine Live Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Varicella Vaccine Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global Varicella Vaccination Market Research Report 2025

Global Live Attenuated Vaccine for Chickenpox Market Research Report 2025

Global Nasal Spray Live Attenuated Vaccine Market Research Report 2024

Global Acyclovir Injection Market Research Report 2024

Global Herpes Zoster Treatment Market Insights Forecast to 2030

Global Mumps Virus Vaccine Live Market Research Report 2024

Global Poultry Live Vaccines Market Research Report 2025

Global Live Poultry Vaccine Market Research Report 2025

Human Varicella Zoster Immunoglobulin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions